RNS Number : 8960A
Kromek Group PLC
25 January 2024

25 January 2024

Kromek Group plc
("Kromek" or the "Group")

Kromek receives £1.4m order to deliver D3M detectors for use in EU Stockpile

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it has received an order in excess of £1.4m to supply D3M detectors and associated networkable solutions. The revenues are expected to be received within the current financial year.

The detectors are intended for use in the rescEU stockpile, which is being developed by the European Commission to help safeguard citizens from disasters and manage emerging risks, including equipment to respond to chemical, biological, radiological, and nuclear (CBRN) risks. The order is fully funded by the EU, through the Directorate-General for European Civil Protection and Humanitarian Aid Operations.

Arnab Basu, CEO of Kromek, said: "Amid increasingly fraught and volatile global relations, the need for sovereign nations to prepare for emerging risks has never been more important.

"We are pleased to be able to contribute positively to global efforts to safeguard citizens against possible threats, accidental or deliberate.

"This latest order for Kromek's D3M line of detectors is another endorsement of our world-leading technology, which is amongst the most versatile and sensitive available, offering real time data of any potential nuclear threat so that decision making can be rapid and responses can be co-ordinated effectively."

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Paul Farquhar, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCQELBLZFLFBBZ